These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35114995)

  • 1. Decolonizing harm reduction.
    Lasco G
    Harm Reduct J; 2022 Feb; 19(1):8. PubMed ID: 35114995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principles, practice, and policy vacuums: Policy actor views on provincial/territorial harm reduction policy in Canada.
    Hyshka E; Anderson-Baron J; Pugh A; Belle-Isle L; Hathaway A; Pauly B; Strike C; Asbridge M; Dell C; McBride K; Tupper K; Wild TC
    Int J Drug Policy; 2019 Sep; 71():142-149. PubMed ID: 30711412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bangkok 2004. The spread of harm-reduction programs in Brazil.
    Teixeira LP
    HIV AIDS Policy Law Rev; 2004 Dec; 9(3):94-5. PubMed ID: 15812931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decolonizing drug policy.
    Daniels C; Aluso A; Burke-Shyne N; Koram K; Rajagopalan S; Robinson I; Shelly S; Shirley-Beavan S; Tandon T
    Harm Reduct J; 2021 Nov; 18(1):120. PubMed ID: 34838050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harm Reduction Policies Where Drugs Constitute a Security Issue.
    Narvaez-Chicaiza MA
    Health Care Anal; 2020 Dec; 28(4):382-390. PubMed ID: 33136222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity?
    Ekhtiari H; Noroozi A; Farhoudian A; Radfar SR; Hajebi A; Sefatian S; Zare-Bidoky M; Razaghi EM; Mokri A; Rahimi-Movaghar A; Rawson R
    Addiction; 2020 Jul; 115(7):1395-1403. PubMed ID: 31737965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworks.
    Hyshka E; Anderson-Baron J; Karekezi K; Belle-Isle L; Elliott R; Pauly B; Strike C; Asbridge M; Dell C; McBride K; Hathaway A; Wild TC
    Harm Reduct J; 2017 Jul; 14(1):50. PubMed ID: 28747183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harm reduction as a complex adaptive system: A dynamic framework for analyzing Tanzanian policies concerning heroin use.
    Ratliff EA; Kaduri P; Masao F; Mbwambo JK; McCurdy SA
    Int J Drug Policy; 2016 Apr; 30():7-16. PubMed ID: 26790689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harm reduction in Europe: a framework for civil society-led monitoring.
    Rigoni R; Tammi T; van der Gouwe D; Schatz E
    Harm Reduct J; 2021 Jan; 18(1):3. PubMed ID: 33407566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harm Reduction and Moral Desert in the Context of Drug Policy.
    Porter LB
    Health Care Anal; 2020 Dec; 28(4):362-371. PubMed ID: 33108558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two steps forward, one step back: current harm reduction policy and politics in the United States.
    Nadelmann E; LaSalle L
    Harm Reduct J; 2017 Jun; 14(1):37. PubMed ID: 28606093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A national public health programme on gambling policy development in New Zealand: insights from a process evaluation.
    Kolandai-Matchett K; Landon J; Bellringer M; Abbott M
    Harm Reduct J; 2018 Mar; 15(1):11. PubMed ID: 29510708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strengthening drug policy and practice through ethics engagement: an old challenge for a new harm reduction.
    Irwin KS; Fry CL
    Int J Drug Policy; 2007 Mar; 18(2):75-83. PubMed ID: 17689348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harm reduction drug policy in Israel: what has been accomplished and what still needs to be done?
    Bonny-Noach H
    Isr J Health Policy Res; 2019 Oct; 8(1):75. PubMed ID: 31619286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug consumption rooms: Comparing times, spaces and actors in issues of social acceptability in French public debate.
    Jauffret-Roustide M; Cailbault I
    Int J Drug Policy; 2018 Jun; 56():208-217. PubMed ID: 29754895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decolonizing global health: what should be the target of this movement and where does it lead us?
    Kwete X; Tang K; Chen L; Ren R; Chen Q; Wu Z; Cai Y; Li H
    Glob Health Res Policy; 2022 Jan; 7(1):3. PubMed ID: 35067229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV and AIDS among adolescents who use drugs: opportunities for drug policy reform within the sustainable development agenda.
    Tinasti K
    J Int AIDS Soc; 2018 Feb; 21 Suppl 1(Suppl Suppl 1):. PubMed ID: 29485748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How the harm reduction movement contrasts itself against punitive prohibition.
    Tammi T; Hurme T
    Int J Drug Policy; 2007 Mar; 18(2):84-7. PubMed ID: 17689349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harm Reduction Works: Evidence and Inclusion in Drug Policy and Advocacy.
    Klein A
    Health Care Anal; 2020 Dec; 28(4):404-414. PubMed ID: 33079317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When grammars collide: Harm reduction, drug detention and the challenges of international policy reform efforts in Vietnam.
    Edington C; Bayer R
    Glob Public Health; 2013; 8 Suppl 1():S75-91. PubMed ID: 23363324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.